Comment on: Selvin et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013;62:2116-2121

Diabetes

Volumn 62, Issue 10, 2013, Pages

  Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN RECEPTOR;

CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); DIABETES MELLITUS; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LETTER; MORTALITY; PRIORITY JOURNAL; CARDIOVASCULAR DISEASE; FEMALE; MALE; METABOLISM; NOTE;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; RECEPTORS, IMMUNOLOGIC;

EID: 84891503764     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1004     Document Type: Letter

References (5)

1. Selvin E, Halushka MK, Rawlings AM, et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013;62:2116-2121
2. Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) 2010;2:1184-1195
3. Nin JW, Jorsal A, Ferreira I, et al. Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes 2010;59:2027-2032
4. Semba RD, Ferrucci L, Sun K, et al. Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women. Aging Clin Exp Res 2009;21:182-190
5. Fukami A, Adachi H, Yamagishi S, et al. Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population. Metabolism 2009;58:1688-1693